Broad cellular targets in rapidly dividing cells

Broad cellular targets in rapidly dividing cells is a collective term describing the various molecular components and biological processes essential for cell replication that are exploited by traditional cytotoxic chemotherapy (National Cancer Institute, 2023). These targets are not limited to a single receptor or enzyme but encompass a wide range of machinery, including genomic DNA (targeted by alkylating agents like cisplatin), enzymes involved in nucleotide synthesis such as dihydrofolate reductase (targeted by methotrexate), and structural proteins like tubulin that form the mitotic spindle (targeted by taxanes) (StatPearls, 2023; PubMed, 24703533). The therapeutic rationale is based on the fact that malignant cells typically exhibit higher rates of proliferation than most normal somatic cells, making them more susceptible to agents that disrupt the cell cycle and induce apoptosis (American Cancer Society, 2024). However, because these targets are also vital for the function of healthy, rapidly dividing tissues—such as hematopoietic stem cells in the bone marrow and epithelial cells in the gastrointestinal tract—drugs hitting these targets often cause significant systemic toxicities (NIH, PMC3100745). While modern oncology has shifted toward more specific molecularly targeted therapies, these broad cellular targets remain the foundation of many standard-of-care regimens for both solid tumors and hematologic malignancies.

Other names

Cytotoxic chemotherapy targetsProliferation-associated targetsAntineoplastic targetsConventional chemotherapy targets

Interference with DNA integrity through alkylation or intercalation, inhibition of essential metabolic enzymes (antimetabolites), and disruption of the mitotic spindle apparatus (National Cancer Institute, 2023).